This offers the potential for targeted drug therapy of clinically symptomatic visual hallucinations in patients with schizophrenia using acetylcholinesterase inhibition. Methods: A systematic ...

Cholinesterase inhibitors all inhibit the acetylcholinesterase enzyme, thereby increasing the amount of available acetylcholine. The differing pharmacodynamic and pharmacokinetic profiles of the ...

This article looks at the rationale behind the combined use of acetylcholinesterase inhibitors and the N-methyl-D-aspartate-receptor antagonist, memantine, from both preclinical and clinical ...

Zunveyl is a next-generation acetylcholinesterase inhibitor approved in the U.S. for mild-to-moderate Alzheimer's disease. The deal value is $44 million, including $6 million in total upfront ...

ZUNVEYL is a next generation acetylcholinesterase inhibitor approved in the US for the treatment of mild-to-moderate Alzheimer’s disease. Terms of the agreement total $44 million, which includes ...

ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects.

This means that their nerve cells lose the ability to talk to each other properly. Cholinesterase inhibitors, like donepezil, rivastigmine and galantamine, can boost acetylcholine levels. This helps ...